Citadel Advisors
CRVS icon

Citadel Advisors’s Corvus Pharmaceuticals CRVS Stock Holding History

Citadel Advisors’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.95M Sell
397,951
-44,571
-10% -$619K ﹤0.01% 4431
2026
Q1 		$6.47M Buy
442,522
+234,340
+113% +$3.74M ﹤0.01% 3929
2025
Q4 		$1.6M Buy
208,182
+165,416
+387% +$1.3M ﹤0.01% 6366
2025
Q3 		$315K Buy
+42,766
New +$219K ﹤0.01% 10248
2025
Q2 		– Sell
-61,676
Closed -$224K – 12877
2025
Q1 		$196K Sell
61,676
-17,036
-22% -$80.2K ﹤0.01% 10478
2024
Q4 		$421K Sell
78,712
-18,361
-19% -$137K ﹤0.01% 8941
2024
Q3 		$513K Buy
97,073
+44,063
+83% +$158K ﹤0.01% 8208
2024
Q2 		$96.5K Buy
+53,010
New +$98.8K ﹤0.01% 10968
2024
Q1 		– Sell
-7,654
Closed -$16K – 14663
2023
Q4 		$13.5K Buy
7,654
+7,471
+4,083% +$10.9K ﹤0.01% 12929
2023
Q3 		$267 Buy
+183
New +$387 ﹤0.01% 14104
2023
Q1 		– Sell
-1,015
Closed -$863 – 14821
2022
Q4 		$863 Buy
+1,015
New +$898 ﹤0.01% 14570
2022
Q2 		– Sell
-404,545
Closed -$496K – 13017
2022
Q1 		$663K Buy
404,545
+336,465
+494% +$616K ﹤0.01% 8706
2021
Q4 		$165K Buy
+68,080
New +$264K ﹤0.01% 12137
2021
Q3 		– Sell
-29,278
Closed -$86.7K – 13886
2021
Q2 		$78K Sell
29,278
-34,993
-54% -$96.3K ﹤0.01% 13089
2021
Q1 		$198K Buy
+64,271
New +$232K ﹤0.01% 11715
2020
Q3 		– Sell
-15,519
Closed -$42K – 10147
2020
Q2 		$42K Sell
15,519
-29,743
-66% -$87.9K ﹤0.01% 9377
2020
Q1 		$95K Buy
+45,262
New +$184K ﹤0.01% 8659
2019
Q1 		– Sell
-16,904
Closed -$62K – 9331
2018
Q4 		$62K Sell
16,904
-4,360
-21% -$29.7K ﹤0.01% 8429
2018
Q3 		$182K Buy
+21,264
New +$213K ﹤0.01% 8278

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Citadel Advisors's CRVS Position: Q2 2026 in Review

Citadel Advisors reduced its Corvus Pharmaceuticals (CRVS) stake by 10% in Q2 2026, selling an estimated $619K and leaving 397,951 shares worth $5.95M. The position accounts for ﹤0.01% of the portfolio, ranked #4431.

Citadel Advisors first reported a position in CRVS in Q3 2018 and has held it in 19 quarters since. The position peaked at $6.47M in Q1 2026. 174 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • Citadel Advisors held 397,951 shares of Corvus Pharmaceuticals worth $5.95M as of Q2 2026.
  • Citadel Advisors sold 44,571 Corvus Pharmaceuticals shares in Q2 2026, an estimated $619K.
  • Corvus Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #4431 holding.
  • Citadel Advisors first reported a position in Corvus Pharmaceuticals in Q3 2018 and has held it in 19 quarters since.
  • Citadel Advisors's Corvus Pharmaceuticals position peaked at $6.47M in Q1 2026.
  • 174 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.